Results 141 to 150 of about 29,286 (231)

A Comprehensive Echocardiographic Assessment of Patients With Chronic Myeloid Leukemia on Dasatinib

Echocardiography, Volume 43, Issue 6, June 2026.
In a retrospective cohort of 199 adult patients with CML on Dasatinib in a single quaternary center, approximately 25% patients had routine baseline and follow‐up echocardiogram. Dasatinib was associated with significant changes in structural and diastolic parameters.
Chen Chen, Vinesh Appadurai, Maria Paulina Hernandez, Jessica Altman, Nausheen Akhter   +4 more
wiley   +1 more source

Co‐pathologies and biological processes beyond amyloid‐beta and tau in people with Alzheimer's disease: Evidence from clinical cohort studies

Journal of Internal Medicine, Volume 299, Issue 6, Page 694-710, June 2026.
Abstract Alzheimer's disease (AD) is neuropathologically defined by amyloid‐beta (Aβ) plaques and tau neurofibrillary tangles. However, co‐pathologies and other pathobiological processes are involved in the pathogenesis of AD, contributing to neurodegeneration and clinical symptoms.
Daniel Ferreira, Tomasz Chmiela, Maria Eriksdotter, Clifford R. Jack Jr., Grégoria Kalpouzos, Anna Marseglia, Patrizia Mecocci, Agneta Nordberg, Dorota Religa, Eric Westman   +9 more
wiley   +1 more source

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial. [PDF]

Blood Cancer J
Ureshino H, Murai K, Kumagai T, Mino T, Nishiwaki K, Wakita S, Takeoka T, Mita M, Yoshida C, Uoshima N, Fukushima T, Kuroda J, Kondo T, Chiba M, Miyazaki T, Io K, Ueda T, Ono T, Usuki K, Yamauchi T, Fujimaki K, Ikezoe T, Kawaguchi A, Kimura S.   +23 more
europepmc   +1 more source

Reconsidering dual <i>BCR::ABL1</i> inhibition in Philadelphia chromosome-positive acute lymphoblastic leukemia: is sequential better than concurrent? [PDF]

Transl Cancer Res
Ishii H, Ishii S, Arakawa Y, Yano S.
europepmc   +1 more source

Reversible Dasatinib-Associated Pulmonary Hypertension Managed With Dual Therapy and Hemodynamic-Guided Withdrawal. [PDF]

JACC Case Rep
Balmori GT, Alania Torres EM, Rodríguez Pichardo YM, Utrilla AC, Muñoz AV.   +4 more
europepmc   +1 more source

Preparation and characterization of dasatinib solvates

, 2016
Dasatiniba solvātu iegūšana un raksturošana. Čerņavska K., Darba vadītājs vadošā pētniece Dr. chem. Orola L., Maģistra darbs, 51 lappuses, 24 attēli, 18 tabulas, 71 literatūras avoti. Latviešu valodā.
Čerņavska, Kristīne
core  

Development of Colonic Polyposis in a Woman With Chronic Myeloid Leukemia Treated With Dasatinib. [PDF]

Case Rep Hematol
Pelaez G, Yildiz BS, Candan M, Ismail M, Vacca F, Ruzinova MB, Ballentine S, Byrnes K, Ghobadi A.   +8 more
europepmc   +1 more source

Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid leukemia. [PDF]

Cancer Chemother Pharmacol
Verhagen NE, Touw DCW, van den Heuvel JJMW, van den Broek PH, Blijlevens NMA, Janssen JJWM, Koenderink JB, Russel FGM.   +7 more
europepmc   +1 more source

RETRACTED: Kim et al. Inhibition of EphA2 by Dasatinib Suppresses Radiation-Induced Intestinal Injury. <i>Int. J. Mol. Sci.</i> 2020, <i>21</i>, 9096. [PDF]

Int J Mol Sci
Kim A, Seong KM, Choi YY, Shim S, Park S, Lee SS.   +5 more
europepmc   +1 more source

Multimodal gene and targeted drug therapy for chronic myelogenous leukemia using BIM/MCL-1 chimeric nanoparticle: computational target analysis and therapeutic validation. [PDF]

Nano Converg
Lugin ML, Lei W, Lee RT, Chung JY, Katritsis NM, Hwang W, Fleischman AG, Han N, Kwon YJ.   +8 more
europepmc   +1 more source